EUVIMEDEUVIMED entdecken
Crossref

Targeted Nanostructured Lipid Carrier for Brain Delivery of Artemisinin: Design, Preparation, Characterization, Optimization and Cell Toxicity

Jaber Emami, Hessam Yousefian, Hojjat Sadeghi

Journal of Pharmacy & Pharmaceutical Sciences · 28.09.2018 · 21 (1s) · 225s-241s

DOI: 10.18433/jpps30117 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy & Pharmaceutical Sciences, online erschienen am 28.09.2018. Verfasst von Jaber Emami und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics and Isfahan Pharmaceutical Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical…. Hauptthemen laut MEDLINE: Drug Delivery Systems, Drug Design. Die Arbeit wurde bisher 66-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the present study, a transferrin-conjugated nanostructured lipid carrier (TF-NLCs) for brain delivery of artemisinin (ART) was developed. ART-loaded NLCs (ART-NLCs) were prepared using solvent evaporation method and the impact of various formulation or process variables on the responses were assessed using a Taguchi design. Optimized ART-NLC was then coupled with transferrin as targeting ligand and its in vitro cytotoxicity was investigated against U-87MG brain cancer cell line. As a result, the following values are suggested by the software to prepare the optimized formulation: 20 mg Compritol®, 0.25% Tween 80, 5 mg oleic acid, 2.5 mL dichloromethane and 4 min sonication. Mean particle size (PS), zeta potential (ZP), polydispersity index (PDI), entrapment efficiency (EE), mean release time (MRT) of adopted formulation were confirmed to be 145 ± 12.5 nm, 24.3 ± 1.5 mV, 0.513 ± 0.021, 82.3 ± 7.3 % and 24.0 ± 1.1 h, respectively. Following conjugation of optimized ART-NLCs with TF, PS and MRT were increased, while ZP, and EE were decreased significantly. TF-ART-NLCs showed higher cytotoxic activity compared to non-targeted NLCs and free drug. These results indicated that the TF-ART-NLCs could potentially be exploited as a delivery system for anticancer and antimalarial drug ART in brain tumors and malaria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Delivery SystemsDrug DesignAntimalarialsAntineoplastic AgentsArtemisininsBrainCell Line, TumorCell ProliferationCell SurvivalDose-Response Relationship, DrugDrug CarriersDrug Screening Assays, AntitumorHumansLipidsMalariaNanostructuresParasitic Sensitivity TestsParticle SizeStructure-Activity RelationshipTransferrin

Substanzen

AntimalarialsAntineoplastic AgentsArtemisininsDrug CarriersLipidsTransferrinartemisinin

Autor:innen und Institutionen

  • Department of Pharmaceutics and Isfahan Pharmaceutical Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.

Zitieren

APA

Emami, J., Yousefian, H., & Sadeghi, H. (2018). Targeted Nanostructured Lipid Carrier for Brain Delivery of Artemisinin: Design, Preparation, Characterization, Optimization and Cell Toxicity. Journal of Pharmacy & Pharmaceutical Sciences, 21(1s), 225s-241s. https://doi.org/10.18433/jpps30117

Vancouver

Emami J, Yousefian H, Sadeghi H. Targeted Nanostructured Lipid Carrier for Brain Delivery of Artemisinin: Design, Preparation, Characterization, Optimization and Cell Toxicity. Journal of Pharmacy & Pharmaceutical Sciences. 2018;21(1s):225s-241s. doi:10.18433/jpps30117

BibTeX
@article{Emami2018,
  author = {Emami, Jaber and Yousefian, Hessam and Sadeghi, Hojjat},
  title = {Targeted Nanostructured Lipid Carrier for Brain Delivery of Artemisinin: Design, Preparation, Characterization, Optimization and Cell Toxicity},
  journal = {Journal of Pharmacy & Pharmaceutical Sciences},
  year = {2018},
  volume = {21},
  number = {1s},
  pages = {225s--241s},
  doi = {10.18433/jpps30117}
}
Kostenlos starten →